NR546 Week 4 Midterm Exam Due
1st February 2026 Complete Actual
Exam Questions 1- 75 NR546
Psychopharmacology for the
PMHNP NR 546 Midterm and Finals
Examplify Online Proctored Exam
Questions and Answers | 100%
Pass Guaranteed | Graded A+
Section I: Neurobiology & Mechanism of Action (Questions 1-20)
1. A PMHNP is explaining to a student how second messengers work. Which
statement best describes the role of a second messenger?
A. It directly binds to the GABA-A receptor to open the chloride channel.
B. It transports neurotransmitters back into the presynaptic neuron.
C. It amplifies the intracellular signal initiated by a neurotransmitter binding to a
receptor.
D. It degrades monoamines in the synaptic cleft.
,,answer,,,,: C
,*Rationale: Second messengers (e.g., cAMP, IP3) amplify signals within the cell
after a first messenger (neurotransmitter) activates a G-protein coupled receptor .*
2. A patient's depression is believed to be related to low levels of norepinephrine
and serotonin, but also to alterations in intracellular signaling. Which medication
class directly inhibits the reuptake of both serotonin and norepinephrine without
directly acting on intracellular machinery?
A. MAOI
B. SSRI
C. SNRI
D. Tricyclic Antidepressant (TCA)
,,answer,,,,: C
Rationale: SNRIs (e.g., venlafaxine, duloxetine) block the reuptake pumps
(transporters) for both serotonin and norepinephrine .
3. The PMHNP understands that the "lock and key" model of pharmacodynamics
refers to:
A. The drug's ability to cross the blood-brain barrier based on lipid solubility.
B. The specific binding of a drug to a receptor to initiate or block a response.
C. The metabolism of a drug by the cytochrome P450 enzyme system.
D. The excretion of a drug through the renal system.
,,,answer,,,,: B
Rationale: This model describes the specificity of a drug (key) binding to a
receptor (lock) to cause a pharmacological effect .
4. Which intracellular signaling cascade is primarily implicated in the long-term
neuroplasticity effects of antidepressants and is the target of ketamine?
A. Adenylyl cyclase-cAMP pathway
B. Phospholipase C-IP3 pathway
C. mTOR (mammalian target of rapamycin) pathway
D. Arachidonic acid cascade
,,answer,,,,: C
Rationale: Ketamine's rapid antidepressant effect is linked to glutamate modulation
leading to activation of the mTOR pathway, which increases synaptogenesis .
5. A patient is prescribed a medication that acts as an agonist at the dopamine D2
receptor. What effect would the PMHNP expect?
A. Decreased dopaminergic transmission
B. Activation of the post-synaptic neuron
C. Antipsychotic effects
D. Blockade of calcium channels
, ,,answer,,,,: B
Rationale: An agonist binds to and activates the receptor, mimicking the effect of
the endogenous neurotransmitter .
6. What is the primary rate-limiting step in the synthesis of serotonin (5-HT)?
A. Conversion of tyrosine to L-DOPA
B. Conversion of tryptophan to 5-hydroxytryptophan (5-HTP) via tryptophan
hydroxylase
C. Decarboxylation of 5-HTP to serotonin
D. Conversion of glutamate to GABA
,,answer,,,,: B
Rationale: Tryptophan hydroxylase is the rate-limiting enzyme for serotonin
synthesis .
7. The PMHNP is reviewing a patient's genetic testing results. A patient with a poor
metabolizer phenotype for CYP2D6 is started on fluoxetine. What is the primary
risk?
A. Therapeutic failure due to rapid excretion
B. Increased risk of adverse effects due to elevated drug levels
C. Immediate allergic reaction
1st February 2026 Complete Actual
Exam Questions 1- 75 NR546
Psychopharmacology for the
PMHNP NR 546 Midterm and Finals
Examplify Online Proctored Exam
Questions and Answers | 100%
Pass Guaranteed | Graded A+
Section I: Neurobiology & Mechanism of Action (Questions 1-20)
1. A PMHNP is explaining to a student how second messengers work. Which
statement best describes the role of a second messenger?
A. It directly binds to the GABA-A receptor to open the chloride channel.
B. It transports neurotransmitters back into the presynaptic neuron.
C. It amplifies the intracellular signal initiated by a neurotransmitter binding to a
receptor.
D. It degrades monoamines in the synaptic cleft.
,,answer,,,,: C
,*Rationale: Second messengers (e.g., cAMP, IP3) amplify signals within the cell
after a first messenger (neurotransmitter) activates a G-protein coupled receptor .*
2. A patient's depression is believed to be related to low levels of norepinephrine
and serotonin, but also to alterations in intracellular signaling. Which medication
class directly inhibits the reuptake of both serotonin and norepinephrine without
directly acting on intracellular machinery?
A. MAOI
B. SSRI
C. SNRI
D. Tricyclic Antidepressant (TCA)
,,answer,,,,: C
Rationale: SNRIs (e.g., venlafaxine, duloxetine) block the reuptake pumps
(transporters) for both serotonin and norepinephrine .
3. The PMHNP understands that the "lock and key" model of pharmacodynamics
refers to:
A. The drug's ability to cross the blood-brain barrier based on lipid solubility.
B. The specific binding of a drug to a receptor to initiate or block a response.
C. The metabolism of a drug by the cytochrome P450 enzyme system.
D. The excretion of a drug through the renal system.
,,,answer,,,,: B
Rationale: This model describes the specificity of a drug (key) binding to a
receptor (lock) to cause a pharmacological effect .
4. Which intracellular signaling cascade is primarily implicated in the long-term
neuroplasticity effects of antidepressants and is the target of ketamine?
A. Adenylyl cyclase-cAMP pathway
B. Phospholipase C-IP3 pathway
C. mTOR (mammalian target of rapamycin) pathway
D. Arachidonic acid cascade
,,answer,,,,: C
Rationale: Ketamine's rapid antidepressant effect is linked to glutamate modulation
leading to activation of the mTOR pathway, which increases synaptogenesis .
5. A patient is prescribed a medication that acts as an agonist at the dopamine D2
receptor. What effect would the PMHNP expect?
A. Decreased dopaminergic transmission
B. Activation of the post-synaptic neuron
C. Antipsychotic effects
D. Blockade of calcium channels
, ,,answer,,,,: B
Rationale: An agonist binds to and activates the receptor, mimicking the effect of
the endogenous neurotransmitter .
6. What is the primary rate-limiting step in the synthesis of serotonin (5-HT)?
A. Conversion of tyrosine to L-DOPA
B. Conversion of tryptophan to 5-hydroxytryptophan (5-HTP) via tryptophan
hydroxylase
C. Decarboxylation of 5-HTP to serotonin
D. Conversion of glutamate to GABA
,,answer,,,,: B
Rationale: Tryptophan hydroxylase is the rate-limiting enzyme for serotonin
synthesis .
7. The PMHNP is reviewing a patient's genetic testing results. A patient with a poor
metabolizer phenotype for CYP2D6 is started on fluoxetine. What is the primary
risk?
A. Therapeutic failure due to rapid excretion
B. Increased risk of adverse effects due to elevated drug levels
C. Immediate allergic reaction
